Hi, today we are going to talk about Merck & Co. and its current landscape.
Merck & Co. shares are in evidence today as was unveiled that the company it's going to acquire ArQule for $20 per share in cash, totalizing a deal of $2.7 billion. In this season of Mergers and Acquisitions, the Merck & Co. move is based on its interest in pushing its already established leadership on the Cancer-Drug Race, since the company has the top-selling immunotherapy drug Keytruda, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Merck & Co. shares are in evidence today as was unveiled that the company it's going to acquire ArQule for $20 per share in cash, totalizing a deal of $2.7 billion. In this season of Mergers and Acquisitions, the Merck & Co. move is based on its interest in pushing its already established leadership on the Cancer-Drug Race, since the company has the top-selling immunotherapy drug Keytruda, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Igor Silva · análise técnica e sistemas quantitativos
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
Igor Silva · análise técnica e sistemas quantitativos
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.